Role of Real-World Evidence in the Evolving Treatment Landscape of Multiple Myeloma
AJMC,
AJMC® Peer Exchange™ provides a multi-stakeholder perspective on important issues facing managed care professionals in the…
AJMC® Peer Exchange™ provides a multi-stakeholder perspective on important issues facing managed care professionals in the…
ABECMATM is the first personalized cell therapy available to Canadian patients for the treatment of adults with multiple…
ABECMA TM is the first personalized cell therapy available to Canadian patients for the treatment of adults with multiple…
ABECMA TM is the first personalized cell therapy available to Canadian patients for the treatment of adults with multiple…
Health Canada Approves ABECMA™ (idecabtagene vicleucel), the First and Only Anti-BCMA CAR T cell Therapy for Relapsed and…
ABECMA TM is the first personalized cell therapy available to Canadian patients for the treatment of adults with multiple…
ABECMA TM is the first personalized cell therapy available to Canadian patients for the treatment of adults with multiple…
March 27, 2021 02:59 UTC Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time…
FDA Approves Abecma PRINCETON, N.J.,
Br Bristol Myers Squibb is now the only company with two approved CAR T cell therapies with distinct targets of CD19 and BCMA.
PRINCETON, N.J.,
March 27, 2021 02:59 UTC Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time…
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class…
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class…
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class…
PRINCETON, N.J.,
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class…
(NYSE:) and. (NASDAQ:) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene…
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class…
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class…
Treatment with idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, induced clinically meaningful…
Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) was found to yield clinically…
A potentially safer NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) inhibitor that more selectively…